Abstract
Acute renal failure (ARF) is a syndrome of abrupt decline in renal function induced by a number of different insults. In clinic, the common etiology for ARF is ischemia-reperfusion injury (IRI). The pathophysiological process of renal IRI is complex, there is no good treatment. Stem cell therapy is a new and promising treatment for renal IRI. Mesenchymal stem cells (MSCs) have the ability to differentiate into tissues of mesodermal lineages. MSCs are under intensive study as potential therapeutic strategy for renal IRI. MSCs have been investigated with immunomodulatory, anti-inflammatory and tissue repair properties which could attenuate ischemic injury and accelerate the regeneration process in the condition of renal IRI. Moreover, the MSCs have the ability to migrate to the injury sites and to stimulate repair by paracrine mechanisms rather by differentiating into the injured cells. Here we review the latest information on MSCs, their biological characteristics, including their therapeutic perspectives, and envisage their putative role in renal ischaemic conditioning.
Keywords: Differentiation, immunomodulatory, ischemia-reperfusion injury, kidney, mesenchymal stem cells, paracrine.
Current Stem Cell Research & Therapy
Title:Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives
Volume: 12 Issue: 3
Author(s): Honglin Hu and Cong Zou
Affiliation:
Keywords: Differentiation, immunomodulatory, ischemia-reperfusion injury, kidney, mesenchymal stem cells, paracrine.
Abstract: Acute renal failure (ARF) is a syndrome of abrupt decline in renal function induced by a number of different insults. In clinic, the common etiology for ARF is ischemia-reperfusion injury (IRI). The pathophysiological process of renal IRI is complex, there is no good treatment. Stem cell therapy is a new and promising treatment for renal IRI. Mesenchymal stem cells (MSCs) have the ability to differentiate into tissues of mesodermal lineages. MSCs are under intensive study as potential therapeutic strategy for renal IRI. MSCs have been investigated with immunomodulatory, anti-inflammatory and tissue repair properties which could attenuate ischemic injury and accelerate the regeneration process in the condition of renal IRI. Moreover, the MSCs have the ability to migrate to the injury sites and to stimulate repair by paracrine mechanisms rather by differentiating into the injured cells. Here we review the latest information on MSCs, their biological characteristics, including their therapeutic perspectives, and envisage their putative role in renal ischaemic conditioning.
Export Options
About this article
Cite this article as:
Hu Honglin and Zou Cong, Mesenchymal Stem Cells in Renal Ischemia-Reperfusion Injury: Biological and Therapeutic Perspectives, Current Stem Cell Research & Therapy 2017; 12 (3) . https://dx.doi.org/10.2174/1574888X11666161024143640
DOI https://dx.doi.org/10.2174/1574888X11666161024143640 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Biological Evaluation of Ligands Selective for the Melanocortin-3 Receptor
Current Topics in Medicinal Chemistry Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors
Current Medicinal Chemistry Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Pharmacological Potential of Tetrahydrofurano/Pyrano Quinoline and Benzo[b]furoindolyl Derivatives in Acute Inflammation, Pain and Oxidative Stress
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry New Insights in Research About Acute Ischemic Myocardial Injury and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Analysis of the Clinical Diagnostic Value of GMFB in Cerebral Infarction
Current Pharmaceutical Biotechnology Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets The Cardiac Microvasculature in Hypertension, Cardiac Hypertrophy and Diastolic Heart Failure
Current Vascular Pharmacology Brain Excitatory/Inhibitory Circuits Cross-Talking with Chromogranin A During Hypertensive and Hibernating States
Current Medicinal Chemistry Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Triple Threat: The Na+/Ca2+ Exchanger in the Pathophysiology of Cardiac Arrhythmia, Ischemia and Heart Failure
Current Drug Targets CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology The Nrf2-ARE Pathway: A Valuable Therapeutic Target for the Treatment of Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Vitamins in the Prevention or Delay of Cognitive Disability of Aging
Current Aging Science Sepsis-induced Cardiomyopathy
Current Cardiology Reviews The Adipose Tissue as a Source of Vasoactive Factors
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Use of Genomics and Proteomics for the Recognition of Transplantation Rejection of Solid Organs
Recent Patents on DNA & Gene Sequences